GMI Home Log In / Sign Up
Article Publish Status: FREE
Abstract Title:

Hypometabolism as a therapeutic target in Alzheimer's disease.

Abstract Source:

BMC Neurosci. 2008 ;9 Suppl 2:S16. Epub 2008 Dec 3. PMID: 19090989

Abstract Author(s):

Lauren C Costantini, Linda J Barr, Janet L Vogel, Samuel T Henderson

Article Affiliation:

Accera Inc., Interlocken Crescent, Broomfield, CO 80021, USA. lcostantini@accerapharma.com

Abstract:

The pathology of Alzheimer's disease (AD) is characterized by cerebral atrophy in frontal, temporal, and parietal regions, with senile plaques, dystrophic neurites, and neurofibrillar tangles within defined areas of the brain. Another characteristic of AD is regional hypometabolism in the brain. This decline in cerebral glucose metabolism occurs before pathology and symptoms manifest, continues as symptoms progress, and is more severe than that of normal aging. Ketone bodies are an efficient alternative fuel for cells that are unable to metabolize glucose or are 'starved' of glucose. AC-1202 is designed to elevate serum ketone levels safely. We previously showed that treatment with AC-1202 in patients with mild-to-moderate AD improves memory and cognition. Treatment outcomes were influenced by apolipoprotein E genotype status. These data suggest that AC-1202 may be an effective treatment for cognitive dysfunction by providing an alternative substrate for use by glucose-compromised neurons.

Study Type : Review

Print Options


Disqus

Login to Comment

Commenting is limited to Members only. If you are already a member, please login to post a comment. If you do not have a member account and would like to become a member, please click here to begin the process to become a member.